VivaLNK’s Wearable ECG Patch Used in Study of Autonomic Function in Predicting Heart Disease

CAMPBELL, Calif., Aug. 28, 2019 /PRNewswire/ — VivaLNK, a leading provider of connected healthcare solutions, announces an agreement to provide its medical wearable ECG sensors to Emory University for a study to evaluate autonomic function in predicting coronary artery disease (CAD) and its relationship to depression and long-term outcomes. The study builds upon previous work by Emory researchers titled Circadian Autonomic Inflexibility: A Marker of Ischemic Heart Disease, which associates lower heart rate variability (HRV) with subclinical myocardial ischemia.

The VivaLNK medical wearable ECG patch contains an electrocardiography sensor and accelerometer to capture and generate multiple physiological data including ECG trace, heart rate, RR-interval, and 3-axis motion. About the size of a small bandage, the reusable and rechargeable patch weighs a mere 7.5 grams, and can be worn continuously for 72 hours at-a-time to capture and transmit data in real time.

“VivaLNK’s ECG patch is very small and comfortable to wear, which are important factors for clinical use and long-term ECG monitoring,” said Amit Shah, MD, Assistant Professor of Epidemiology at the Rollins School of Public Health at Emory University. “In addition, the software development kit makes it easy to use the patch for research and product development purposes.”

As part of the study, the device will be used to remotely monitor patients who are undergoing coronary angiography, in order to measure autonomic function. Participants will be monitored using the ECG patch for continuous 72-hour periods in a clinical and ambulatory environment, which offers a more complete picture in a natural setting. The research goal is to better understand the role of the autonomic nervous system in depression and coronary artery disease, and to develop better tools for clinical assessment.

For more information on the VivaLNK ECG Patch visit: https://www.vivalnk.com/ecg-monitor.

About VivaLNK
VivaLNK is a provider of connected healthcare solutions for wellness, patient care, and telemedicine. The company’s portfolio includes wearable medical grade devices and data analytics applications that continuously monitor the health and well-being of individuals. The company’s vision is to improve the quality and accessibility of healthcare worldwide by combining technology, data, and analytics into an integrated solution.

Media Contact:
pr@VivaLNK.com

 

View original content:http://www.prnewswire.com/news-releases/vivalnks-wearable-ecg-patch-used-in-study-of-autonomic-function-in-predicting-heart-disease-300907984.html

SOURCE VivaLNK

Staff

Recent Posts

Nutriband Provides Clinical and Regulatory Path Overview for Lead Product – AVERSA(R) Fentanyl Transdermal Patch

NDA will be primarily based on a single Phase 1 human abuse potential clinical study…

2 hours ago

Life Chemicals Partners With Bioz to Provide Customers With Product Usage Information From Scientific Literature

PALO ALTO, CA / ACCESSWIRE / March 27, 2024 / Bioz, Inc., a scientific research-focused…

2 hours ago

Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia

LUND, SWEDEN / ACCESSWIRE / March 27, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq…

5 hours ago

RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

Relief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors OverhaulGENEVA, SWITZERLAND / ACCESSWIRE /…

5 hours ago

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Pivotal Trial for Improving Overall Function and Quality of LifeSALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, a pioneer…

14 hours ago

AARC Celebrates Introduction of the SOAR Act in the House of Representatives

Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…

17 hours ago